Instructions for Montelair (montelukast) pills
English Product Name
Montelair
Release Form Montelair
tab., covered with film, 10 mg: 14 or 28 pcs.
Description
Beige-colored, rectangular, rounded, double-convex tablets with the "10" mark on one side; the bending view is a uniform white mass.
1 tab
montelukast sodium 10.4 mg,
which corresponds to the content of montelukast 10 mg
Auxiliary substances: lactose monohydrate - 89.1 mg, hyprolose (type EF) - 4 mg, microcrystalline cellulose - 89 mg, sodium crocarmellose - 6 mg, magnesium stearate - 1.5 mg.
The shell composition: opadrae beige - 5 mg (hypromellose - 3.13 mg, titanium dioxide - 1.52 mg, macrogol 400 - 0.31 mg, iron (III) dye yellow oxide - 0.04 mg, iron (III) dye red oxide - 3 mcg).
7 pcs. - blisters (2) - cardboard packs.
7 pcs. - blisters (4) - cardboard packs.
14 pcs - blisters (1) - cardboard packs.
14 pcs - blisters (2) - cardboard packs.
ATX codes
R03DC03 Montelukast
Clinical and pharmacological groups / Group affiliation
Leukotriene receptor antagonist. Drug for the treatment of asthma and allergic rhinitis
Active ingredient
montelukast
Pharmacotherapeutic group Montelair
Leukotriene receptor antagonist
Montelukast is a leukotriene receptor antagonist with high selectivity and affinity for cyslt1 receptors. It binds to these receptors without affecting other pharmacologically important airway receptors, such as prostaglandin receptors, cholinergic receptors, or β-adrenergic receptors.
Montelukast inhibits the physiologic effects of cisgeinyl leukotrienes ltc4, ltd4, and lte4 by binding to cyslt1 receptors. It does not stimulate these receptors but rather inhibits them, which may relieve the bronchospasm caused by inhaling ltd4 in patients with asthma.
A 5-mg dose of montelukast alone is sufficient to reverse ltd4-induced bronchospasm.
Montelukast, taken by mouth, causes bronchodilation for 2 hours. It can also complement bronchodilation caused by beta2-agonists.
Testimony Montelair
- Prevention and long-term management of asthma, including prevention of day and night symptoms; treatment of asthma in patients who are sensitive to acetylsalicylic acid;
- and prevention of exercise-induced bronchospasm.\n
- Relaxation of day and night symptoms of seasonal allergic rhinitis.
Method of use, course and dosage Montelair
The internal dosage and regimen of the drug are adjusted individually, based on the patient’s indications, age, and form of drug used.
Additionally, montelukast can be added to treatment with bronchodilators and inhaled corticosteroids.
Nosology Montelair (ICD codes)
J30.1
Allergic rhinitis caused by pollen
J45
Asthma